drugset / Trial / NCT00002202

A Comparison of 141W94 and Indinavir in HIV-Infected Patients

NCT00002202 ↗

Phase 3 Completed 460 enrolled Glaxo Wellcome
Treatment

Summary

The purpose of this study is to see if 141W94 is as safe and effective as indinavir when used with nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks. This study also examines what effect other drugs have on how the body handles 141W94.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject INDINAVIR ANHYDROUS Other / unclassified — —
Background Amprenavir Other / unclassified — —